Website profile

Pr Newswire

PR Newswire’s news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.

  • 6,002articles · 30d
  • 1+ day agolatest article
  • Aug 14, 2026earliest in window
  • 92%with images
  • 272avg words
articles per day
Categories
  • Economy, Business & Finance 2,820
  • Finance & Business 2,249
  • News 1,510
  • Business & Industrial 789
  • Science & Technology 654
  • Health & Wellness 609
  • Medical 563
  • Arts, Culture, Entertainment & Media 529

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

@PRNewswire
prnewswire.com > news-releases > vascarta-outlines-vas-101s-vasceptor-potential-as-a-non-opioid-advance-in-pain-medicine-across-sickle-cell-disease-osteoarthritis-and-cancer-302858963.html

Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer

2+ week, 4+ day ago   (157+ words) Aug 25, 2026, 07:45 ET A Common Pathway Behind Very Different Pains Vasceptor is built on Vascarta's patented Vasporta™ gel-based delivery platform, which, combined with a small-molecule active pharmaceutical ingredient such as curcumin, is designed to cross the skin and reach plasma and…...